prikaz prve stranice dokumenta Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
  Download
PDF 900.3 KB
Scientific paper - Original scientific paper
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
Radiology and Oncology, 57 (2023), 3; 397-404. https://doi.org/10.2478/raon-2023-0040
Ljubičić, Lidija; Janzic, Urska; Unk, Mojca; Terglav, Ana Sophie; Mohorcic, Katja; Seiwerth, Fran; Bitar, Lela; Badovinac, Sonja; Pleština, Sanja; Korsic, Marta; Kukulj, Suzana; Samarzija, Miroslav; Jakopović, Marko

Cite this document

Ljubičić, L., Janzic, U., Unk, M., Terglav, A. S., Mohorcic, K., Seiwerth, F. ... Jakopović, M. (2023). Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Radiology and Oncology, 57. (3), 397-404. doi: 10.2478/raon-2023-0040

Ljubičić, Lidija, et al. "Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis." Radiology and Oncology, vol. 57, no. 3, 2023, pp. 397-404. https://doi.org/10.2478/raon-2023-0040

Ljubičić, Lidija, Urska Janzic, Mojca Unk, Ana Sophie Terglav, Katja Mohorcic, Fran Seiwerth, Lela Bitar, et al. "Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis." Radiology and Oncology 57, no. 3 (2023): 397-404. https://doi.org/10.2478/raon-2023-0040

Ljubičić, L., et al. (2023) 'Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis', Radiology and Oncology, 57(3), pp. 397-404. doi: 10.2478/raon-2023-0040

Ljubičić L, Janzic U, Unk M, Terglav AS, Mohorcic K, Seiwerth F, and sur.. Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis. Radiology and Oncology [Internet]. 2023 September 01 [cited 2024 May 11];57(3):397-404. doi: 10.2478/raon-2023-0040

L. Ljubičić, et al., "Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis", Radiology and Oncology, vol. 57, no. 3, pp. 397-404, September 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:427998. [Accessed: 11 May 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
AuthorLidija Ljubičić
AuthorUrska Janzic
AuthorMojca Unk
AuthorAna Sophie Terglav
AuthorKatja Mohorcic
AuthorFran Seiwerth
AuthorLela Bitar
AuthorSonja Badovinac
AuthorSanja Pleština
AuthorMarta Korsic
AuthorSuzana Kukulj
AuthorMiroslav Samarzija
AuthorMarko Jakopović
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Abstract (english)
Background: The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option. Patients and methods: A multicenter retrospective trial of real-life treatment patterns and outcomes of patients with advanced lung adenocarcinoma treated with docetaxel plus nintedanib after the failure of ICI and/or ChT was performed. Patients from 2 Slovenian and 1 Croatian oncological center treated between June 2014 and August 2022 were enrolled. We assessed objective response (ORR), disease control rate (DCR), median progression free survival (PFS), median overall survival (OS), and safety profile of treatment. Results: There were 96 patients included in the analysis, with ORR of 18.8%, DCR of 57.3%, median PFS of 3.0 months (95% CI: 3.0-5.0 months), and a median OS of 8.0 months (95% CI: 7.0-10.0 months). The majority of patients (n = 47,49%) received docetaxel plus nintedanib as third-line therapy. The ORR for this subset of patients was 19.1%, with a DCR of 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination of ChT-ICI therapy (n = 24), with an ORR of 29.2% and DCR of 66.7% and median PFS of 4.0 months (95% CI: 3.0-8.0 months). Fifty-three patients (55.2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30.2%), and increased liver enzyme levels (n = 17, 17.7%). Conclusions: The combination of docetaxel and nintedanib can be considered an effective therapy option with an acceptable toxicity profile for patients with advanced NSCLC after the failure of ICI +/- ChT.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleRadiology and Oncology
Numberingvol. 57, no. 3, pp. 397-404
e-ISSN1581-3207
DOIhttps://doi.org/10.2478/raon-2023-0040
URN:NBNurn:nbn:hr:184:427998
Publication2023-09-01
Document URLhttps://www.sciendo.com/article/10.2478/raon-2023-0040
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-11-13 13:03:41